Malaga Cove Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Malaga Cove Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,598	Closed	-$2.27M	–	174
2021 Q4	$2.27M	Sell	3,598 -72	-2%	-$44.3K	0.89%	29
2021 Q3	$2.22M	Sell	3,670 -10	-0.3%	-$6.21K	0.92%	26
2021 Q2	$2.06M	Buy	3,680 +12	+0.3%	+$6.08K	0.88%	31
2021 Q1	$1.74M	Buy	3,668 +5	+0.1%	+$2.43K	0.74%	43
2020 Q4	$1.78M	Buy	3,663 +520	+17%	+$281K	0.84%	33
2020 Q3	$1.76M	Sell	3,143 -11	-0.3%	-$6.67K	1.02%	19
2020 Q2	$1.97M	Hold	3,154	–	–	1.2%	14
2020 Q1	$1.53M	Hold	3,154	–	–	1.26%	16
2019 Q4	$1.18M	Sell	3,154 -66	-2%	-$22.2K	0.73%	43
2019 Q3	$893K	Sell	3,220 -19	-0.6%	-$5.62K	0.6%	59
2019 Q2	$1.01M	Buy	3,239 +351	+12%	+$117K	0.65%	46
2019 Q1	$1.19M	Hold	2,888	–	–	0.73%	36
2018 Q4	$1.07M	Hold	2,888	–	–	0.74%	34
2018 Q3	$1.18M	Buy	2,888 +6	+0.2%	+$2.28K	0.64%	45
2018 Q2	$994K	Sell	2,882 -6	-0.2%	-$1.88K	0.5%	65
2018 Q1	$995K	Buy	+2,888	New	+$1M	0.53%	61

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Malaga Cove Capital's REGN Position: Q1 2022 in Review

Malaga Cove Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 3,598 shares — an estimated $2.27M sold.

Malaga Cove Capital first reported a position in REGN in Q1 2018 and held it in 16 quarters. The position peaked at $2.27M in Q4 2021. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Malaga Cove Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Malaga Cove Capital sold 3,598 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $2.27M.
Malaga Cove Capital first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 16 quarters.
Malaga Cove Capital's Regeneron Pharmaceuticals position peaked at $2.27M in Q4 2021.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Malaga Cove Capital's 13F filing for Q1 2022, filed 28 Apr 2022.